Latest Communications

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.

12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners

13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.


About Us
Corporate Strategy
Contacts

Vision

To become a leading Company Delivering,
Funding and Supporting Innovation in Healthcare.

Mission

To pursue a new strategic approach in
Healthcare Innovation through the combined:


Delivery

of innovative, patent protected, well differentiated products/technologies with improved efficacy, safety or delivery system;

Creation

of successful business ventures by providing partners with a balanced mix of equity investment and development know how;

Support

to companies or inventors in shaping and bringing to fruition their innovative projects and ideas.



Search results